Akeso

Recent Finacing

Series D

Recent Raise

$150M

Akeso is a Zhongshan-based clinical-stage biopharmaceutical company discovering and developing in-house mono- and bispecific antibody therapeutics for oncology and autoimmune indications, advancing PD-1–targeted bispecifics through clinical trials.